John E.  Sagartz net worth and biography

John Sagartz Biography and Net Worth

Insider of Inotiv
John Sagartz has been the chief strategy officer at Inotiv since November 2018, working to help define and accelerate plans for the company’s growth. Sagartz founded and led Seventh Wave Laboratories for over 15 years, prior to Inotiv’s legacy company, BASi, acquiring Seventh Wave’s operations in July of 2018. Following the acquisition, he joined Inotiv’s board of directors to help guide operations to provide broader solutions and greater scientific expertise to the company’s clients.

Dr. Sagartz began his career as a toxicologic pathologist at Searle/Monsanto in 1996. There, he held positions of increasing responsibility as section head, director, preclinical development site head, and fellow, following Monsanto’s merger with Pharmacia. After Pfizer’s acquisition of Pharmacia in 2003, John served Seventh Wave as president and chief executive officer, and chief strategy officer. He received his Bachelor of Science and Doctor of Veterinary Medicine degrees from Kansas State University and, after completing residency training in anatomic pathology, earned his Doctor of Philosophy from The Ohio State University.

What is John E. Sagartz's net worth?

The estimated net worth of John E. Sagartz is at least $7.57 million as of March 14th, 2023. Dr. Sagartz owns 692,047 shares of Inotiv stock worth more than $7,570,994 as of March 28th. This net worth approximation does not reflect any other investments that Dr. Sagartz may own. Additionally, Dr. Sagartz receives a salary of $438,610.00 as Insider at Inotiv. Learn More about John E. Sagartz's net worth.

How old is John E. Sagartz?

Dr. Sagartz is currently 58 years old. There are 8 older executives and no younger executives at Inotiv. The oldest executive at Inotiv is Dr. Peter T. Kissinger, Founder, Chairman Emeritus & Scientific Advisor, who is 79 years old. Learn More on John E. Sagartz's age.

What is John E. Sagartz's salary?

As the Insider of Inotiv, Inc., Dr. Sagartz earns $438,610.00 per year. There are 3 executives that earn more than Dr. Sagartz. The highest earning executive at Inotiv is Dr. Adrian Hardy Ph.D., Executive VP of Global Marketing & Corporate Development, who commands a salary of $2,740,000.00 per year. Learn More on John E. Sagartz's salary.

How do I contact John E. Sagartz?

The corporate mailing address for Dr. Sagartz and other Inotiv executives is 2701 KENT AVENUE, WEST LAFAYETTE IN, 47906. Inotiv can also be reached via phone at (765) 463-4527 and via email at [email protected]. Learn More on John E. Sagartz's contact information.

Has John E. Sagartz been buying or selling shares of Inotiv?

John E. Sagartz has not been actively trading shares of Inotiv during the last quarter. Learn More on John E. Sagartz's trading history.

Who are Inotiv's active insiders?

Inotiv's insider roster includes Philip Downing (VP), and John Sagartz (Insider). Learn More on Inotiv's active insiders.

Are insiders buying or selling shares of Inotiv?

During the last year, Inotiv insiders bought shares 2 times. They purchased a total of 52,966 shares worth more than $163,803.92. The most recent insider tranaction occured on December, 14th when insider Michael Garrett bought 5,000 shares worth more than $14,150.00. Insiders at Inotiv own 5.8% of the company. Learn More about insider trades at Inotiv.

Information on this page was last updated on 12/14/2023.

John E. Sagartz Insider Trading History at Inotiv

See Full Table

John E. Sagartz Buying and Selling Activity at Inotiv

This chart shows John E. Sagartz's buying and selling at Inotiv by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Inotiv Company Overview

Inotiv logo
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company offers research and discovery services, including computational toxicology, disease pharmacology, DMPK, safety pharmacology, discovery bioanalysis, exploratory, surgical models and medical device, and cell and molecular biology; non-clinical safety assessment includes general and genetic toxicology, regulated bioanalysis, carcinogenicity studies, and development and reproductive toxicology; pathology services, such as histology, digital, clinical, and medical device pathology; bioanalysis includes nonregulated discovery bioanalysis, biotherapeutics, and regulated preclinical and clinical bioanalysis; proteomics; and consulting services, as well as model and research services. The company operates in the United States, the Netherlands, and internationally. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Read More

Today's Range

Now: $10.94
Low: $10.35
High: $11.19

50 Day Range

MA: $6.32
Low: $3.27
High: $11.04

2 Week Range

Now: $10.94
Low: $1.61
High: $11.42

Volume

309,450 shs

Average Volume

382,750 shs

Market Capitalization

$282.14 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

3.13